CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis.
Mason U, Aldrich J, Breedveld F, Davis CB, Elliott M, Jackson M, Jorgensen C, Keystone E, Levy R, Tesser J, Totoritis M, Truneh A, Weisman M, Wiesenhutter C, Yocum D, Zhu J.
Mason U, et al. Among authors: truneh a.
J Rheumatol. 2002 Feb;29(2):220-9.
J Rheumatol. 2002.
PMID: 11838838
Clinical Trial.